Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by Invesco Ltd.

Invesco Ltd. boosted its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 451.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 203,404 shares of the company's stock after purchasing an additional 166,526 shares during the period. Invesco Ltd.'s holdings in Dr. Reddy's Laboratories were worth $3,212,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of RDY. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Dr. Reddy's Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after acquiring an additional 9,373,412 shares during the last quarter. Aikya Investment Management Ltd boosted its position in Dr. Reddy's Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock worth $88,590,000 after purchasing an additional 4,523,303 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Dr. Reddy's Laboratories by 397.2% during the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after purchasing an additional 3,911,404 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Dr. Reddy's Laboratories by 462.1% during the 4th quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock valued at $44,444,000 after purchasing an additional 2,313,987 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its stake in shares of Dr. Reddy's Laboratories by 402.5% in the 4th quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock valued at $38,981,000 after purchasing an additional 1,977,419 shares during the period. Institutional investors and hedge funds own 3.85% of the company's stock.

Dr. Reddy's Laboratories Stock Performance

RDY stock traded up $0.12 during midday trading on Friday, hitting $13.95. 224,389 shares of the stock traded hands, compared to its average volume of 1,471,100. The stock's fifty day simple moving average is $13.21 and its 200-day simple moving average is $14.18. The firm has a market cap of $11.64 billion, a P/E ratio of 22.21 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a 1-year low of $12.26 and a 1-year high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.